| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Dalbavancin |
| Brand | Xydalba® |
| Indication | Indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. |
| Assessment Process | |
| Rapid review commissioned | 07/03/2017 |
| Rapid review completed | 28/04/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price |
The HSE has approved reimbursement following confidential price negotiations November 2017.